tiprankstipranks
Fresh Tracks Therapeutics, Inc. (FRTX)
OTHER OTC:FRTX

Fresh Tracks Therapeutics (FRTX) AI Stock Analysis

Compare
507 Followers

Top Page

FR

Fresh Tracks Therapeutics

(OTC:FRTX)

42Neutral
Fresh Tracks Therapeutics faces significant financial performance challenges due to ongoing losses and negative cash flow, despite some revenue growth and a strong equity position. Technical indicators suggest the stock may be overbought, increasing the risk of a price pullback. The negative P/E ratio and lack of dividend yield further weigh on its valuation, leading to a generally unfavorable outlook.

Fresh Tracks Therapeutics (FRTX) vs. S&P 500 (SPY)

Fresh Tracks Therapeutics Business Overview & Revenue Model

Company DescriptionFresh Tracks Therapeutics (FRTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies targeting dermatological diseases and conditions. Operating within the biotechnology and healthcare sectors, FRTX is dedicated to addressing unmet medical needs through its diverse pipeline of therapeutic candidates, leveraging cutting-edge research and development to deliver effective solutions to patients.
How the Company Makes MoneyFresh Tracks Therapeutics generates revenue primarily through the development and commercialization of its proprietary dermatological therapies. The company seeks to monetize its therapeutic candidates through various channels, including direct sales of approved products, collaborative partnerships with larger pharmaceutical companies, and licensing agreements. These partnerships often involve milestone payments and royalties, providing a significant boost to the company's earnings. Additionally, FRTX may engage in research and development collaborations, receiving funding and support in exchange for sharing intellectual property or co-developing products. These revenue streams are pivotal in sustaining the company's operations and fueling further innovation in its pipeline.

Fresh Tracks Therapeutics Financial Statement Overview

Summary
Fresh Tracks Therapeutics shows some positive revenue growth and strong equity positioning, but persistent operational losses, negative margins, and cash flow challenges hinder financial stability. The company must focus on achieving profitability and improving cash flow sustainability to enhance its financial outlook.
Income Statement
40
Negative
The company has shown a positive revenue growth rate of 15.32% from 2022 to 2023, which is a positive trend. However, the net profit margin remains negative due to consistent net losses, and margins such as EBIT and EBITDA are also negative, indicating ongoing operational challenges. Profitability remains a significant concern despite revenue gains.
Balance Sheet
60
Neutral
The balance sheet reflects a relatively strong equity position with zero total debt and a high equity ratio. However, the company has experienced decreasing total assets over the years, and while the debt-to-equity ratio is favorable, the company needs to maintain asset growth for improved financial health.
Cash Flow
45
Neutral
The company's free cash flow has improved significantly, showing a positive growth rate, but it remains negative overall. The operating cash flow to net income ratio indicates stronger cash flow management compared to prior periods, yet continued negative cash flows highlight ongoing liquidity issues.
Breakdown
Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
8.01M6.94M404.00K1.82M7.92M
Gross Profit
8.01M-7.10M-27.83M-9.39M-12.30M
EBIT
-6.36M-21.53M-40.24M-20.98M-24.47M
EBITDA
-5.65M-21.06M-39.38M-20.90M-24.47M
Net Income Common Stockholders
-5.69M-20.66M-39.52M-20.90M-25.95M
Balance SheetCash, Cash Equivalents and Short-Term Investments
10.87M8.68M26.88M30.11M7.23M
Total Assets
11.59M10.27M29.72M33.63M18.14M
Total Debt
0.0049.00K69.00K511.00K151.00K
Net Debt
-10.87M-8.63M-26.82M-29.60M-7.08M
Total Liabilities
1.66M3.08M4.81M6.50M10.57M
Stockholders Equity
9.93M7.19M24.91M27.14M7.57M
Cash FlowFree Cash Flow
-4.34M-19.38M-36.18M-20.06M-35.99M
Operating Cash Flow
-4.34M-19.34M-36.15M-20.03M-35.98M
Investing Cash Flow
0.00-47.00K-36.00K4.48M32.51M
Financing Cash Flow
6.53M1.18M32.95M38.44M2.64M

Fresh Tracks Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.94
Price Trends
50DMA
0.82
Positive
100DMA
0.77
Positive
200DMA
0.82
Positive
Market Momentum
MACD
0.03
Positive
RSI
79.31
Negative
STOCH
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FRTX, the sentiment is Positive. The current price of 0.94 is above the 20-day moving average (MA) of 0.93, above the 50-day MA of 0.82, and above the 200-day MA of 0.82, indicating a bullish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 79.31 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FRTX.

Fresh Tracks Therapeutics Risk Analysis

Fresh Tracks Therapeutics disclosed 23 risk factors in its most recent earnings report. Fresh Tracks Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Fresh Tracks Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$1.73B-113.76%229.74%70.23%
49
Neutral
$6.86B0.03-54.79%2.48%24.62%-2.84%
48
Neutral
$448.11M-43.42%-5.97%-25.87%
48
Neutral
$39.75M108.28%57.84%
42
Neutral
$5.59M-57.34%
41
Neutral
$381.02M111.29%15.33%61.49%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FRTX
Fresh Tracks Therapeutics
0.94
0.04
4.44%
EYPT
EyePoint Pharmaceuticals
6.52
-14.78
-69.39%
RVNC
Revance Therapeutics
3.65
-1.29
-26.11%
NRXP
NRX Pharmaceuticals
2.35
-2.80
-54.37%
ARQT
Arcutis Biotherapeutics
14.62
4.38
42.77%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.